Morningstar

GSK Stops Development of Drug Candidate for Chronic Cough

Provided by Dow Jones

By Adria Calatayud 




  GSK said it decided to halt the development of an experimental drug as a treatment for chronic cough after the medicine missed the key goal in a late-stage clinical study. 



  The U.K. drugmaker said Friday that the drug, camlipixant, achieved mixed results in two trials--with one hitting the primary objective of significant reductions in cough frequency after 12 weeks of treatment and a second falling short for the same goal after 24 weeks. 



  The aggregate data point to limited efficacy that is unlikely to transform patient care, GSK said. As a result, the company decided to discontinue further development of camlipixant in refractory chronic cough, it added. 



  A mid-stage trial for the same drug in adults with irritable bowel syndrome with diarrhea and mixed bowel habits will continue to evaluate efficacy and safety, GSK said. 





  Write to Adria Calatayud at adria.calatayud@wsj.com 





  (END) Dow Jones Newswires



  July 17, 2026 05:04 ET (09:04 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
September Stock Market Outlook: How to Position Your Portfolio During a Risky Stage
 
Excluding just seven stocks from our valuation, the remaining market is trading at fair value. 
 
 
David Sekera, CFA 
 
 
 
If You’re Worried About Your Bond Portfolio, You’re Missing the Point
 
For the safe part of your portfolio, err on the side of caution and get out of the timing business. 
 
 
Christine Benz 
 
 
 
Worried About a Stock Market Bubble? Here Are 5 Ways to Stay Invested
 
Here’s how concerned investors can participate in the US stock market while managing its risks. 
 
 
Dan Lefkovitz 
 
 
 
The 10 Best Dividend Stocks
 
These are the top dividend-paying stocks to buy today. 
 
 
Susan Dziubinski 
 
 
 
TIPS Look Tempting. Should You Buy?
 
Treasury Inflation-Protected Securities are sporting some of the highest yields ever, but there are a few caveats for investors to consider before making a purchase. 
 
 
Jeffrey Ptak, CFA 
 
 
 
 

			Sponsor Center